Last checked at (Sharecast News) - Clinical stage biotechnology company PureTech Health said on Thursday that its affiliate, Vedanta Biosciences, has been awarded a $5.8m grant for its 'VE707' programme, targeting multidrug resistant infections.
The FTSE 250 company said the grant was awarded to Vedanta by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which it described as a global non-profit partnership dedicated to accelerating early development in antibacterial research and development, to address the rising global threat of drug-resistant bacteria.
It said Vedanta Biosciences is eligible for $3.5m in further funding upon completion of specific milestones.
"Increasingly the human microbiome is being colonised by dangerous bacteria and other microorganisms that have developed resistance to antimicrobial drugs, mainly through poor global stewardship of antibiotics," said PureTech president and chief of business and strategy Bharatt Chowrira.
"This grant from CARB-X recognises Vedanta's unique platform and advanced understanding of the human gut microbiome for developing live biotherapeutic products with the potential to modulate the intestinal microbiome to address a range of significant human diseases and health issues, including drug-resistant pathogens."
23 Mar 2023 07:24
US Royalty Pharma strikes deal with PureTech Health on KarXT royalties
(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.
Read more